• Cav2.1 Recruitment in Developing PV Synapses

  2026-10-13

  Singh et al. examined how developmental NMDAR signaling shapes Cav2.1-dependent GABA release from cortical parvalbumin interneurons. Their findings support a maturation role for NMDARs in presynaptic function, while remaining limited to a mouse cellular model rather than demonstrating a clinical mechanism for schizophrenia.

• ML133 HCl and Kir2.1 in Pulmonary Vascular Remodeling

  2026-10-13

  A 2022 study linked Kir2.1 activity with pulmonary artery smooth muscle cell proliferation and migration through a proposed TGF-β1/SMAD2/3 connection. The findings support a mechanistic hypothesis for pulmonary vascular remodeling, but their pharmacological and model-specific design does not establish clinical efficacy or therapeutic suitability for ML133 HCl.

• What GlycoRNA–RBP Surface Domains Suggest

  2026-10-12

  A preprint reports RNA-binding-protein nanoclusters associated with glycoRNAs on living-cell surfaces and links these domains to TAT peptide entry. The findings are provocative but remain limited by preprint status, uncertain generality, and the distinction between surface association and direct membrane anchoring.

• CAR Macrophages for Peritoneal Metastasis

  2026-10-12

  A source-grounded overview of a preclinical study evaluating mRNA lipid-nanoparticle programming of CAR macrophages, including its research question, conceptual design, reported immune findings, evidence strength, and limitations. The study is distinct from the reporter-chemistry applications of D-Luciferin sodium salt.

• FLCN Variants and mRNA Rescue in BHD

  2026-10-11

  A 2026 study examined two Chinese families with Birt-Hogg-Dubé syndrome, providing genetic and cellular evidence for two FLCN variants and preliminary evidence that FLCN mRNA can restore folliculin-related signaling in vitro. The findings support variant interpretation and a research hypothesis, but they do not establish a clinical mRNA therapy.

• Carbapenemase Transmission in Enterobacter cloacae

  2026-10-10

  A 2025 BMC Microbiology study examined 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong, combining carbapenemase-gene detection, gene-location analysis, transferability testing, mobile-element profiling, and strain typing. The findings show frequent blaNDM-1 carriage, substantial plasmid-associated dissemination, and multidrug resistance, while also highlighting why hospital-level surveillance should not be equated with direct proof of patient-to-patient transmission.

• ER Stress Impairs Intestinal Stem Cells

  2026-10-09

  A 2023 Research Square preprint reports that tunicamycin-induced endoplasmic reticulum stress damages the mouse small-intestinal mucosa, reduces intestinal stem-cell abundance and differentiation, and increases crypt apoptosis. The study links these effects with activation of the GRP78/ATF6/CHOP axis and suppression of p44/42 MAPK signaling, while its preclinical design limits conclusions about human disease and pathway-specific causality.

• Leucovorin Calcium as a Tumor–Stroma Probe

  2026-10-09

  Leucovorin Calcium, also known as calcium folinate, can do more than support methotrexate rescue studies. This article examines its value as a mechanistic reference for interpreting folate metabolism, cell proliferation assays, and drug-response differences in patient-derived gastric cancer assembloids.

• Capecitabine Beyond Tumor-Only Drug Testing

  2026-10-08

  Capecitabine offers translational researchers more than a familiar fluoropyrimidine backbone: it can serve as a probe of enzymatic activation, tumor–stroma interactions, and context-dependent response. Paired conceptually with patient-derived gastric cancer assembloids, the compound helps frame a more rigorous question—whether drug activity remains consistent when epithelial, stromal, and inflammatory biology are modeled together.

• Q-VD-OPh in Apoptosis Research: Evidence and Limits

  2026-10-08

  A source-grounded overview of Q-VD-OPh as a research tool for studying caspase-dependent cell death, with emphasis on apoptosome biology, evidence strength, conceptual applications, and limitations in cryopreservation and neurodegenerative research.

• Ferrostatins, Lipid Damage, and Ferroptosis

  2026-10-07

  Skouta and colleagues showed that ferrostatin-1 protects against ferroptotic cell death primarily by suppressing oxidative lipid damage, rather than by broadly removing all reactive oxygen species. By testing disease-relevant cellular models and developing a mechanistic framework for ferrostatin activity, the study connected membrane lipid peroxidation with diverse neurodegenerative and kidney-related phenotypes while guiding the design of improved analogues.

• CGP 55845 Hydrochloride in GABAB Research

  2026-10-07

  CGP 55845 hydrochloride is a supplier-described selective GABAB receptor antagonist that can help frame questions about presynaptic inhibition and neurotransmitter release modulation. However, the supplied 2025 Glia study investigated astrocytic GAT-3 in the entorhinal cortex–dentate gyrus circuit, not CGP 55845. This overview compares those mechanisms, distinguishes reported findings from interpretation, and outlines evidence limitations. The compound’s published relevance to astrocytic GAT-3, contextual memory, hypoglycemia, and clinical applications remains unestablished.

• Patient-Derived Gastric Cancer Assembloids

  2026-10-06

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine tumor organoids with matched stromal cell populations. The model revealed that stromal context can reshape gene expression and drug sensitivity, supporting more physiologically relevant studies of tumor heterogeneity, resistance, and personalized treatment.

• Verteporfin (CL 318952): Evidence and Research Context

  2026-10-06

  Verteporfin is best established as a light-activated therapy for ocular neovascularization, while proposed light-independent effects on YAP/TEAD signaling, autophagy, apoptosis, and chemoresistance remain model-dependent. This overview compares clinical, mechanistic, and translational evidence and defines the main limits on interpretation.

• Hypoxia-Activated Molecular Glue for Cancer Therapy

  2026-10-05

  Li and colleagues report BNNC, a hypoxia-responsive photomolecular glue designed to release the Cyclin K degrader (R)-CR8 together with the phototherapeutic agent BSS-Et in tumor-associated conditions. The study reports enhanced DNA damage, apoptosis, and tumor-growth suppression compared with either component alone, while also identifying important questions about selectivity, exposure, and translation.

8736 records 1/583 page Next 12345 下5页 Last page